ReviewJournal of neurology2009
Evaluating the progression of Friedreich ataxia and its treatment.
Review in Journal of neurology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 58 citations in OpenAlex.
- Clinical and cognitive assessment in Friedreich ataxia clinical trials: a review.Frontiers in neurology · 2025Review
- The Responsiveness of Gait and Balance Outcomes to Disease Progression in Friedreich Ataxia.Cerebellum (London, England) · 2022Article
- Article
- Measurements of Hand Function in Degenerative Cerebellar Disease: A Case-Control Pilot Study.American journal of physical medicine & rehabilitation · 2020Article
- Multiple mechanisms underpin cerebral and cerebellar white matter deficits in Friedreich ataxia: The IMAGE-FRDA study.Human brain mapping · 2020Article
- Psychometric properties of the Friedreich Ataxia Rating Scale.Neurology. Genetics · 2019Article
- Impact of diabetes in the Friedreich ataxia clinical outcome measures study.Annals of clinical and translational neurology · 2017Article
- Peptide SS-31 upregulates frataxin expression and improves the quality of mitochondria: implications in the treatment of Friedreich ataxia.Scientific reports · 2017Article
- How does performance of the Friedreich Ataxia Functional Composite compare to rating scales?Journal of neurology · 2017Article
- Functional and Gait Assessment in Children and Adolescents Affected by Friedreich's Ataxia: A One-Year Longitudinal Study.PloS one · 2016Article
- Robotic and clinical evaluation of upper limb motor performance in patients with Friedreich's Ataxia: an observational study.Journal of neuroengineering and rehabilitation · 2015Observational
- Highly specific ubiquitin-competing molecules effectively promote frataxin accumulation and partially rescue the aconitase defect in Friedreich ataxia cells.Neurobiology of disease · 2015Article
- Sensitivity of spatiotemporal gait parameters in measuring disease severity in Friedreich ataxia.Cerebellum (London, England) · 2014Article
- Routine clinical testing underestimates proprioceptive deficits in Friedreich's ataxia.Cerebellum (London, England) · 2013Article
- Rating disease progression of Friedreich's ataxia by the International Cooperative Ataxia Rating Scale: analysis of a 603-patient database.Brain : a journal of neurology · 2013Article
- Auditory pathway changes mirror overall disease progress in individuals with Friedreich ataxia.Journal of neurology · 2012Article
- Longitudinal change in dysarthria associated with Friedreich ataxia: a potential clinical endpoint.Journal of neurology · 2012Article
- Ophthalmic features of Friedreich ataxia.Eye (London, England) · 2012Article
- Cardiological manifestations of mitochondrial respiratory chain disorders.Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology · 2011Review
- Impaired myocardial perfusion reserve and fibrosis in Friedreich ataxia: a mitochondrial cardiomyopathy with metabolic syndrome.European heart journal · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Friedreich ataxia is characterised by slowly progressive neurodegeneration and cardiomyopathy. Currently, no treatments have been proven to delay, prevent, or reverse the inexorable decline that occurs in this condition; however, several pharmaceutical agents are undergoing clinical assessment. Because initial beneficial therapies are likely to slow disease progression rather than reverse morbidity, the need for accurate measurement tools that will detect such subtle benefits is critical. The impact of Friedreich ataxia on the nervous system has been assessed largely through the use of rating scales and functional composite measures, and a number of patient reported outcome measures in Friedreich ataxia have been studied. However, on the basis of published reports on the performance of these measures, none clearly stands out as the best for use in clinical trials. Refinement of existing tools and development of new tools will be needed to maximise the chance of detecting small but clinically significant benefits of therapeutic agents in patients with Friedreich ataxia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.